Allurion Technologies

ALUR

Market cap $15.1M

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of the first peer-reviewed study on the consecutive use of the Allurion Smart Capsule, a first of its kind, swallowable, procedure-less weight-loss device. Published in Obesity Surgery, a leading international journal dedicated to the treatment of obesity and metabolic disease, the multicenter, retrospective study demonstrates that two consecu.

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held on October 9, 2025 at the Metropolitan Club in New York City. Management will hold one-on-one meetings with investors throughout the day. Investors can register for the conference by contacting their ROTH Capital Partners representative. About Allurion Allurion is.

Allurion Technologies, Inc. (ALUR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.25 per share a year ago.

Allurion Technologies Inc. (NYSE:ALUR ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Shantanu K. Gaur - Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Tara Brady - Corporate Participant Conference Call Participants Joshua Thomas Jennings - TD Cowen, Research Division Keay Thomas Nakae - Chardan Capital Markets, LLC, Research Division Michael Toomey - Jefferies LLC, Research Division Operator Hello, and thank you for standing by.

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry Signed term sheet with strategic partner to enhance manufacturing and distribution capabilities and R&D pipeline,.

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960.

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a new strategic direction with an increasing focus on low-dose GLP-1 combination therapy, muscle mass maintenance, and US market entry. The company has reported on real-world data from nearly 20,000 patients that demonstrate that patients using the Allurion Program lose weight immediately and through a focus on behavior change, keep the weight off while incre.

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced new publications on long-term weight loss results with the Allurion Program. In the first study, 522 patients treated with the Allurion Program across nine international obesity centers reduced their weight, on average, by 14.4kg (32lbs) or 13.9% of total body weight in just four months. One year later, the average weight loss was 13.9kg (31lbs) or 13.2% of t.

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical's 40-year experience in the Canadian market and reflects Allurion's commitment to establishing a new standard of care in obesity management focused on metabolicall.

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpoints. Topline results announced previously showed that the AUDACITY Study met its first co-primary endpoint related to.